e-learning
resources
Vienna 2009
Monday, 14.09.2009
Severe asthma and its treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma
L. Somerville, J. Bardelas, A. Viegas, P. D‘Andrea, J. Thirlwell, M. Massanari, G. Peachey (Houston, High Point, East Hanover, United States Of America; West Sussex, United Kingdom)
Source:
Annual Congress 2009 - Severe asthma and its treatment
Session:
Severe asthma and its treatment
Session type:
E-Communication Session
Number:
1876
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Somerville, J. Bardelas, A. Viegas, P. D‘Andrea, J. Thirlwell, M. Massanari, G. Peachey (Houston, High Point, East Hanover, United States Of America; West Sussex, United Kingdom). Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma. Eur Respir J 2009; 34: Suppl. 53, 1876
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Efficacy and safety of the short term immunotherapy (SIT) in allergic rhinoconjunctivitis (AR)
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Safety and efficacy of omalizumab in children with allergic asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Efficacy and safety of levocetirizine in persistent allergic rhinitis (PER)
Source: Eur Respir J 2005; 26: Suppl. 49, 136s
Year: 2005
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Evaluation and efficacy of allergen immunotherapy in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 399s
Year: 2005
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Combination of montelukast and loratadine provides added benefit for relief of symptoms of seasonal allergic rhinitis (SAR)
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004
High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
The efficacy of desloratadine in the treatment of allergic rhinitis
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept